ABIONYX Pharma SA (ABNX.PA)
EUR 1.24
(2.15%)
EUR 1.24
(2.15%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -3.51 Million EUR | 18.24% |
| 2022 | -4.3 Million EUR | 26.19% |
| 2021 | -5.83 Million EUR | -209.12% |
| 2020 | -1.88 Million EUR | -202.0% |
| 2019 | 1.84 Million EUR | 129.33% |
| 2018 | -6.3 Million EUR | -26.66% |
| 2017 | -4.97 Million EUR | 79.98% |
| 2016 | -24.87 Million EUR | -49.48% |
| 2015 | -16.63 Million EUR | -153.51% |
| 2014 | -6.56 Million EUR | 15.23% |
| 2013 | -7.74 Million EUR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -2.08 Million EUR | 0.0% |
| 2023 Q4 | -635 Thousand EUR | 0.0% |
| 2023 FY | -3.51 Million EUR | 18.24% |
| 2023 Q1 | -1.12 Million EUR | 32.13% |
| 2023 Q2 | -2.24 Million EUR | -100.0% |
| 2023 Q3 | -635 Thousand EUR | 71.75% |
| 2022 Q3 | -828 Thousand EUR | 67.53% |
| 2022 Q2 | -2.55 Million EUR | -100.0% |
| 2022 Q1 | -1.27 Million EUR | 61.08% |
| 2022 Q4 | -1.65 Million EUR | -100.0% |
| 2022 FY | -4.3 Million EUR | 26.19% |
| 2021 Q2 | -2.54 Million EUR | -100.0% |
| 2021 Q3 | -1.63 Million EUR | 35.66% |
| 2021 Q4 | -3.27 Million EUR | -100.0% |
| 2021 FY | -5.83 Million EUR | -209.12% |
| 2021 Q1 | -1.27 Million EUR | -31.78% |
| 2020 FY | -1.88 Million EUR | -202.0% |
| 2020 Q4 | -966 Thousand EUR | -100.0% |
| 2020 Q3 | -483 Thousand EUR | 47.5% |
| 2020 Q2 | -920 Thousand EUR | -100.0% |
| 2020 Q1 | -460 Thousand EUR | 56.06% |
| 2019 FY | 1.84 Million EUR | 129.33% |
| 2019 Q1 | 1.44 Million EUR | 200.03% |
| 2019 Q4 | -1.04 Million EUR | -100.0% |
| 2019 Q2 | 2.89 Million EUR | 100.0% |
| 2019 Q3 | -523.49 Thousand EUR | -118.08% |
| 2018 Q2 | -1.7 Million EUR | 0.0% |
| 2018 Q1 | -1.7 Million EUR | 20.18% |
| 2018 FY | -6.3 Million EUR | -26.66% |
| 2018 Q4 | -1.44 Million EUR | 0.0% |
| 2018 Q3 | -1.44 Million EUR | 15.1% |
| 2017 FY | -4.97 Million EUR | 79.98% |
| 2017 Q3 | -2.13 Million EUR | -505.1% |
| 2017 Q4 | -2.13 Million EUR | 0.0% |
| 2017 Q1 | -353 Thousand EUR | 93.08% |
| 2017 Q2 | -353 Thousand EUR | 0.0% |
| 2016 Q2 | -7.33 Million EUR | 0.0% |
| 2016 Q4 | -5.1 Million EUR | 0.0% |
| 2016 Q3 | -5.1 Million EUR | 30.37% |
| 2016 Q1 | -7.33 Million EUR | -53.11% |
| 2016 FY | -24.87 Million EUR | -49.48% |
| 2015 FY | -16.63 Million EUR | -153.51% |
| 2015 Q1 | -3.53 Million EUR | -139.88% |
| 2015 Q3 | -4.78 Million EUR | -35.6% |
| 2015 Q2 | -3.53 Million EUR | 0.0% |
| 2015 Q4 | -4.78 Million EUR | 0.0% |
| 2014 Q1 | -1.8 Million EUR | 0.0% |
| 2014 Q3 | -1.47 Million EUR | 18.65% |
| 2014 FY | -6.56 Million EUR | 15.23% |
| 2014 Q4 | -1.47 Million EUR | 0.0% |
| 2014 Q2 | -1.8 Million EUR | 0.0% |
| 2013 FY | -7.74 Million EUR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| ABIVAX Société Anonyme | -147.74 Million EUR | 97.619% |
| Adocia SA | -21.16 Million EUR | 83.376% |
| Aelis Farma SA | -5.07 Million EUR | 30.721% |
| Biophytis S.A. | -17.02 Million EUR | 79.337% |
| Advicenne S.A. | -7.03 Million EUR | 49.964% |
| genOway Société anonyme | 1.56 Million EUR | 324.423% |
| IntegraGen SA | -171.39 Thousand EUR | -1952.521% |
| Medesis Pharma S.A. | -3.95 Million EUR | 11.15% |
| Neovacs S.A. | -8.74 Million EUR | 59.764% |
| NFL Biosciences SA | -3.74 Million EUR | 6.073% |
| Plant Advanced Technologies SA | 79.16 Thousand EUR | 4543.659% |
| Quantum Genomics Société Anonyme | -3.17 Million EUR | -10.945% |
| Sensorion SA | -22.06 Million EUR | 84.055% |
| Theranexus Société Anonyme | -6.82 Million EUR | 48.476% |
| TME Pharma N.V. | -6.73 Million EUR | 47.773% |
| Valbiotis SA | -7.36 Million EUR | 52.253% |
| TheraVet SA | -1.57 Million EUR | -123.976% |
| Valerio Therapeutics Société anonyme | -20.34 Million EUR | 82.707% |
| DBV Technologies S.A. | -67.26 Million EUR | 94.77% |
| Genfit S.A. | -28.89 Million EUR | 87.824% |
| GeNeuro SA | -14.75 Million EUR | 76.16% |
| Innate Pharma S.A. | -7.57 Million EUR | 53.527% |
| Inventiva S.A. | -110.42 Million EUR | 96.814% |
| MaaT Pharma SA | -19.71 Million EUR | 82.158% |
| MedinCell S.A. | -25.03 Million EUR | 85.949% |
| Nanobiotix S.A. | -39.7 Million EUR | 91.139% |
| OSE Immunotherapeutics SA | -23 Million EUR | 84.706% |
| Poxel S.A. | -35.09 Million EUR | 89.974% |
| GenSight Biologics S.A. | -26.22 Million EUR | 86.583% |
| Transgene SA | -22.32 Million EUR | 84.244% |
| Valneva SE | -101.42 Million EUR | 96.532% |